JP2009510134A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510134A5
JP2009510134A5 JP2008533837A JP2008533837A JP2009510134A5 JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5 JP 2008533837 A JP2008533837 A JP 2008533837A JP 2008533837 A JP2008533837 A JP 2008533837A JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5
Authority
JP
Japan
Prior art keywords
gastrin
pharmaceutical composition
seq
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008533837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510134A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/001644 external-priority patent/WO2007041833A1/en
Publication of JP2009510134A publication Critical patent/JP2009510134A/ja
Publication of JP2009510134A5 publication Critical patent/JP2009510134A5/ja
Withdrawn legal-status Critical Current

Links

JP2008533837A 2005-10-07 2006-10-06 Dpp−iv阻害剤およびガストリン化合物の組み合わせ使用 Withdrawn JP2009510134A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72491905P 2005-10-07 2005-10-07
PCT/CA2006/001644 WO2007041833A1 (en) 2005-10-07 2006-10-06 Combined use of dpp iv inhibitors and gastrin compounds

Publications (2)

Publication Number Publication Date
JP2009510134A JP2009510134A (ja) 2009-03-12
JP2009510134A5 true JP2009510134A5 (enExample) 2009-09-24

Family

ID=37942251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533837A Withdrawn JP2009510134A (ja) 2005-10-07 2006-10-06 Dpp−iv阻害剤およびガストリン化合物の組み合わせ使用

Country Status (8)

Country Link
US (2) US20090054314A1 (enExample)
EP (1) EP1951286A4 (enExample)
JP (1) JP2009510134A (enExample)
CN (1) CN101365476A (enExample)
AU (1) AU2006301892A1 (enExample)
BR (1) BRPI0616949A2 (enExample)
CA (1) CA2625150A1 (enExample)
WO (1) WO2007041833A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1486204A (zh) 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
EP1511509B1 (en) 2002-06-07 2007-10-10 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20110020797A1 (en) * 2007-02-09 2011-01-27 Bristol-Myers Squibb Company Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors
JP2010538997A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 肺炎連鎖球菌感染の治療における治療剤としての、フィブリノゲン受容体アンタゴニストおよび/またはゴナドトロピン放出ペプチドの使用
WO2009033700A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of secretin and optionally urodilatin as therapeutic agents
US8404727B2 (en) * 2009-01-07 2013-03-26 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
US8808689B1 (en) * 2012-09-27 2014-08-19 Perle Bioscience, Inc. Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent
KR102697255B1 (ko) 2017-10-19 2024-08-23 데이진 화-마 가부시키가이샤 벤즈이미다졸 유도체 및 이의 용도
EP4603143A3 (en) * 2018-12-28 2025-11-05 Mitsubishi Tanabe Pharma Corporation Crystal of pyrrolidine compound
WO2022261357A2 (en) * 2021-06-10 2022-12-15 City Of Hope Compositions and methods for islet cell transplants

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP2003520226A (ja) * 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−iv阻害剤および抗糖尿病薬剤を含む組合せ物
DE60137216D1 (de) * 2000-03-31 2009-02-12 Prosidion Ltd Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention
CN1486204A (zh) * 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
WO2002079457A1 (en) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
AU2003231864A1 (en) * 2002-05-24 2003-12-12 University Of Alberta Treatment for diabetes
EP1511509B1 (en) * 2002-06-07 2007-10-10 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
BR0315523A (pt) * 2002-10-22 2005-08-30 Waratah Pharmaceuticals Inc Tratamento de diabetes
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
WO2005072045A2 (en) * 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels

Similar Documents

Publication Publication Date Title
JP2009538348A5 (enExample)
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
WO2008131149A3 (en) Crystal forms of saxagliptin and processes for preparing same
JP2009510134A5 (enExample)
EP2341065A3 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4a protease
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
TW200400199A (en) Hepatitis C inhibitor tri-peptides
WO2008021733A3 (en) Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2005028501A1 (en) Macrocyclic peptides active against the hepatitis c virus
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
WO2011080102A3 (en) Glp-1 analogues and derivatives
JP2013503862A5 (enExample)
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
JP2010505831A5 (enExample)
WO2008069917A3 (en) Novel cyclic peptides
JP2010536714A5 (enExample)
JP2006506942A5 (enExample)
JP2006514104A5 (enExample)
JP2017534675A5 (enExample)
MX2010008108A (es) Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.